再普乐是礼来公司的最畅销的药物。
目的：观察再普乐治疗肠易激综合征(IBS)的临床疗效。
Objective: To observe the clinical efficacy of olanzapine in the treatment of patients with irritable bowel syndrome (IBS).
该医生写道，“我询问了再普乐的适用症是什么，因为她当时指出许多医生会为那个患者开具抗精神病药处方。”
I inquired what Zyprexa was indicated for she then indicated that many physicians might prescribe an antipsychotic for this patient.
直到2007年礼来公司才在再普乐的标签中增加了反映药物有导致体重明显增加和血糖改变的趋势的严重警告。
Lilly waited until 2007 to add strong warnings to Zyprexa's label to reflect the drug's tendency to cause severe weight gain and blood sugar changes.
2002年，礼来的再普乐在日本上市仅10个月后，该国的卫生官员就要求礼来公司警告医师不要对糖尿病人开再普乐。
And in 2002, only 10 months after Lilly began selling Zyprexa in Japan, medical regulators in that country required Lilly to warn doctors against using Zyprexa in diabetic patients.
恰恰相反，根据证人john Gueriguian博士的证词，礼来公司出于药品销售的保护而对医生隐瞒了再普乐的风险。
Instead, Lilly hid Zyprexa's risks from doctors to protect the drug's sales, according to the witness, Dr. John Gueriguian.
恰恰相反，根据证人john Gueriguian博士的证词，礼来公司出于药品销售的保护而对医生隐瞒了再普乐的风险。
Instead, Lilly hid Zyprexa's risks from doctors to protect the drug's sales, according to the witness, Dr. John Gueriguian.
应用推荐